Company record · MBX · Pharmaceutical Preparations
MBX Biosciences, Inc.
MBX Biosciences, Inc.'s chief financial officer on the record is John Smither, effective July 13, 2026, per the filing record.
The record holds 1 verified CFO change for MBX Biosciences, Inc. from Form 8-K filings, filed July 13, 2026 and the CFO signature on its 10-K filed March 12, 2026.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled |
|---|---|
| Officer | John Smither |
| Title as printed | Chief Financial Officer and principal financial officer |
| Basis | Latest move: appointment, 8-K filed July 13, 2026 |
Seat timeline
2Every verified record for this seat, newest first, dated as the filing states it.
2026-07-13Appointment
MBX Biosciences, Inc. appoints John Smither as CFOeffective July 13, 2026 · 8-K filed July 13, 2026 · sec.gov, Item 5.02
2026-03-1210-K signature
Richard Bartram signed the annual report as Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
10-K filed March 12, 2026 · sec.gov
“/s/ Richard Bartram Richard Bartram Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)”
Company
| Ticker | MBX |
|---|---|
| SEC CIK | 0001776111 |
| Industry (SIC) | Pharmaceutical Preparations (2834) |
| Roster note | The DEF 14A filed 2026-04-22 also names Richard Bartram alongside a Chief Financial Officer title. An 8-K with Item 5.02 was filed on 2026-10-22, after this 10-K; any CFO change it reports is tracked on the moves record. |
Same industry on the record
8Other companies the roster files under SIC “Pharmaceutical Preparations”.
Cadrenal Therapeutics, Inc.CVKD
Interim CFO: John P. Sharp · effective June 25, 2026
Petros Pharmaceuticals, Inc.PTPI
Departure disclosed · Robert Weinstein · no successor on the record yet
Actinium Pharmaceuticals, Inc.ATNM
CFO: Matt David, M.D. · effective October 14, 2026
Adial Pharmaceuticals, Inc.ADIL
Departure disclosed · Vinay Shah · no successor on the record yet
BeyondSpring Inc.BYSI
CFO: Na Li · effective July 1, 2026
CalciMedica, Inc.CALC
Departure disclosed · Stephen Bardin · no successor on the record yet
Cue Biopharma, Inc.CUE
CFO: James Ahlers · effective July 30, 2026
Emergent BioSolutions Inc.EBS
Change disclosed, effective January 1, 2027 · incoming: Frank Vargo
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.